Wedbush Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)
Wedbush analyst Yun Zhong has reaffirmed a Buy rating on Rocket Pharmaceuticals (RCKT) with a price target of $16.00. Zhong, who has an average return of -9.0% and a 42.50% success rate, also covers other healthcare stocks. Additionally, LifeSci Capital's Cory Jubinville issued a Buy rating for Rocket Pharmaceuticals today, while Needham maintained a Hold rating on the stock.
In a report released today, Yun Zhong from Wedbush reiterated a Buy rating on Rocket Pharmaceuticals, with a price target of $16.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Zhong is an analyst with an average return of -9.0% and a 42.50% success rate. Zhong covers the Healthcare sector, focusing on stocks such as MannKind, Rezolute, and Rocket Pharmaceuticals.
In addition to Wedbush, Rocket Pharmaceuticals also received a Buy from LifeSci Capital’s Cory Jubinville, PhD in a report issued today. However, on the same day, Needham maintained a Hold rating on Rocket Pharmaceuticals (NASDAQ: RCKT).
